Molecular Analysis of Breast Cancer
18 Years
N/A
Female
Breast Cancer, Breast Cancer Non-invasive Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Trial Information
Molecular Analysis of Breast Cancer
The tissue obtained in this protocol will be used for genome-wide examination of DNA, RNA
expression profiling, proteomic analyses, isolation and analyses of normal and cancer stem
cells, isolation and analyses of circulating tumor cells, possible analyses of immune cells,
and possible analyses of serum factors. The tissue may also be used to develop
patient-specific cell culture models or mouse xenograft models of breast cancer for biologic
study of tumor progression and metastases and for therapeutic testing. In general, the
tissue will be used in studies that will molecularly classify tumors, identify prognostic
markers, identify potential therapeutic markers, identify potential treatment targets, and
help us better understand the biology and specific role played by different tumor cells in
the metastatic process.
The ultimate goal is to use molecular analyses to improve the diagnosis and treatment of
breast cancer.
Inclusion Criteria:
People eligible for this study include anyone older than 18 years whois undergoing one of the following procedures: core needle or surgical breast biopsy,
lumpectomy, mastectomy, axillary lymph node surgery, breast reduction surgery, or ductal
lavage or ductoscopy. Patients who have had breast cancer in the past who are currently
free of disease or who have a breast cancer recurrence are also eligible. All patients who
participate must be able to understand and sign the informed consent. Although most
patients will be female, any males undergoing the above procedures are also eligible for
this study.
Exclusion Criteria:Any patient who is less than 18 years old, who is unable to understand
the informed consent, or not undergoing the above procedures will be excluded from this
research.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Principal Investigator
Stefanie S. Jeffrey M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Stanford University
Authority:
United States: Food and Drug Administration
Study ID:
SU-11052007-799
NCT ID:
NCT00569049
Start Date:
May 1996
Completion Date:
Related Keywords:
- Breast Cancer
- Breast Cancer Non-invasive Breast Cancer
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Breast Neoplasms
Name | Location |
|---|---|
| Stanford University School of Medicine | Stanford, California 94305-5317 |
